The following article features coverage from the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Vemurafenib improves outcomes among patients with non–small cell lung cancer (NSCLC) with a BRAFV600 mutation, according to the results of a basket study presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.1

One to 4 percent of patients with NSCLC harbor a BRAFV600 mutation. For the NSCLC cohort of the phase 2 VE-BASKET study (ClinicalTrials.gov Identifier: NCT01524978), researchers evaluated data from 62 patients with NSCLC treated with vemurafenib.

Half of the patients received at least 2 prior therapies.

Of the 8 previously untreated patients, 3 had a confirmed response and 5 had stable disease. Of the 54 previously treated patients, 20 had a confirmed response and 21 had stable disease.

The overall median progression-free survival (PFS) and overall survival (OS) rates were 6.5 and 15.4 months, respectively.

The most common adverse event was nausea; 6 patients discontinued treatment due to serious adverse events, which included keratoacanthoma and squamous cell carcinoma of the skin.

The authors concluded that “vemurafenib showed evidence of encouraging efficacy in [patients] with NSCLC with BRAFV600 mutation, with prolonged PFS in previously untreated [patients]; median OS was not estimable due to ongoing responses. The safety profile of vemurafenib was similar to that seen in melanoma studies.”

RELATED: Midtreatment FDG-PET-Driven RT Escalation Promising in NSCLC

Read more of Cancer Therapy Advisor‘s coverage of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting by visiting the conference page.

Reference

  1. Subbiah V, Gervais R, Riely GJ, et al. Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation. J Clin Oncol. 2017;34(suppl; abstr 9074).